title: Why publish a secondary analysis of only one treatment group in the Behandelstrategieën voor Reumatoide Artritis trial? Comment on the article by van der Bijl et al.
authors.forename: Maarten
authors.initials: M
authors.lastname: Boers
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab; D008727:Methotrexate